RFK Jr. to speed up development and availability of low-cost alternatives to the costliest drugs
The Trump administration moved Wednesday to accelerate the development and availability of a broad class of low-cost, competitive drugs that promise to cut billions of dollars in U.S. spending on pharmaceuticals for diabetes, cancer and other conditions.
Originally published by washingtontimes.com. Syndicated material does not necessarily reflect the views of Vanity Fair Fashion.
